Home MAPK MAPKAPK2

MAPKAPK2

MAPKAPK2 Products

  • All (5)
  • MAPKAPK2 Inhibitors (5)
  • New MAPKAPK2 Products
Catalog No. Product Name Information Product Use Citations Product Validations
S6930 MK2 Inhibitor III MK2 Inhibitor III (MK2-IN-3) is an ATP-competitive MK2 (MAPKAP-K2) inhibitor with an IC50 value of 8.5 nM.
E1657 Gamcemetinib (CC-99677) Gamcemetinib (CC-99677,BMS-986371) is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (MK2) (MAPKAPK2 (MK2)) pathway in both biochemical (IC50=156.3 nM) and cell based assays (EC50=89 nM).
E2407 MK2-IN-1 hydrochloride MK2-IN-1 hydrochloride is a potent and selective MAPKAP-K2 (MK2) inhibitor with IC50 of 0.11 μM with a non-ATP competitive binding mode.
S8224 PF-3644022

PF-3644022 is a potent freely reversible ATP-competitive inhibitor of MAPKAPK2 (MK2) with an Ki of 3 nM. PF-3644022 also potently inhibits TNFα production with an IC50 of 160 nM.
iScience, 2024, 27(4):109339
E1271New Zunsemetinib Zunsemetinib(ATI-450, CDD-450) is a selective inhibitor of p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) that mediates inflammatory responses. It reduces inflammation in cryopyrinopathy, alleviates arthritis, and potentially prevents tachyphylaxis.
S6930 MK2 Inhibitor III MK2 Inhibitor III (MK2-IN-3) is an ATP-competitive MK2 (MAPKAP-K2) inhibitor with an IC50 value of 8.5 nM.
E1657 Gamcemetinib (CC-99677) Gamcemetinib (CC-99677,BMS-986371) is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (MK2) (MAPKAPK2 (MK2)) pathway in both biochemical (IC50=156.3 nM) and cell based assays (EC50=89 nM).
E2407 MK2-IN-1 hydrochloride MK2-IN-1 hydrochloride is a potent and selective MAPKAP-K2 (MK2) inhibitor with IC50 of 0.11 μM with a non-ATP competitive binding mode.
S8224 PF-3644022

PF-3644022 is a potent freely reversible ATP-competitive inhibitor of MAPKAPK2 (MK2) with an Ki of 3 nM. PF-3644022 also potently inhibits TNFα production with an IC50 of 160 nM.
iScience, 2024, 27(4):109339
E1271New Zunsemetinib Zunsemetinib(ATI-450, CDD-450) is a selective inhibitor of p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) that mediates inflammatory responses. It reduces inflammation in cryopyrinopathy, alleviates arthritis, and potentially prevents tachyphylaxis.
E1271New Zunsemetinib Zunsemetinib(ATI-450, CDD-450) is a selective inhibitor of p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) that mediates inflammatory responses. It reduces inflammation in cryopyrinopathy, alleviates arthritis, and potentially prevents tachyphylaxis.

Choose Selective MAPKAPK2 Inhibitors

Tags: MAPKAPK2 antagonist | MAPKAPK2 inhibitor | MAPKAPK2 agonist | MAPKAPK2 activator